Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 539,076
  • Shares Outstanding, K 76,901
  • Annual Sales, $ 143,010 K
  • Annual Income, $ -400,420 K
  • 60-Month Beta 2.61
  • Price/Sales 4.05
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.25
  • Most Recent Earnings -1.72 on 11/07/19
  • Next Earnings Date 05/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.04
  • Number of Estimates 5
  • High Estimate -0.86
  • Low Estimate -1.22
  • Prior Year -2.27
  • Growth Rate Est. (year over year) +54.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.95 +0.86%
on 05/22/20
10.64 -34.12%
on 05/12/20
-2.16 (-23.56%)
since 04/22/20
3-Month
3.62 +93.65%
on 03/17/20
10.70 -34.49%
on 02/24/20
-3.99 (-36.27%)
since 02/21/20
52-Week
2.93 +139.25%
on 10/28/19
17.37 -59.64%
on 12/02/19
-10.28 (-59.46%)
since 05/22/19

Most Recent Stories

More News
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca(R) (rucaparib) in multiple tumor types have been...

CLVS : 7.01 (-6.91%)
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer

FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study....

AZN : 55.22 (-0.11%)
PFE : 37.50 (+0.64%)
MRK : 76.37 (-0.24%)
CLVS : 7.01 (-6.91%)
Clovis Oncology Announces Pricing of Public Offering of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting...

CLVS : 7.01 (-6.91%)
Clovis Oncology Announces Proposed Offering of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.

CLVS : 7.01 (-6.91%)
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer

Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.

PFE : 37.50 (+0.64%)
MRK : 76.37 (-0.24%)
GSK : 40.89 (-0.34%)
CLVS : 7.01 (-6.91%)
Rubraca(R) (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy

--Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical triali

CLVS : 7.01 (-6.91%)
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?

Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CLVS : 7.01 (-6.91%)
Look for Shares of Clovis Oncology to Potentially Pullback after Yesterday's 1.88% Rise

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $8.99 to a high of $9.60. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of...

CLVS : 7.01 (-6.91%)
Pancreatic Cancer Market Latest Trends, Demand and Analysis 2026

According to Stratistics MRC, the is accounted for $1,904.20 million in 2017 and is expected to reach $4,728.19 million by 2026 growing at a CAGR of 10.6% during the forecast period. Advancement of technology...

AMGN : 226.43 (+0.73%)
CELGZ : 0.47 (+2.15%)
CLVS : 7.01 (-6.91%)
PFE : 37.50 (+0.64%)
TEVA : 11.96 (-0.50%)
Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates

Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.

AZN : 55.22 (-0.11%)
GSK : 40.89 (-0.34%)
BMY : 60.79 (-0.57%)
CLVS : 7.01 (-6.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 7.70
1st Resistance Point 7.36
Last Price 7.01
1st Support Level 6.81
2nd Support Level 6.60

See More

52-Week High 17.37
Fibonacci 61.8% 11.85
Fibonacci 50% 10.15
Fibonacci 38.2% 8.45
Last Price 7.01
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar